col-xs-12
col-sm-12
col-md-1
col-lg-1
col-xs-12
col-sm-12
col-md-8
col-lg-8
col-xs-12
col-sm-12
col-md-3
col-lg-3
col-xs-12
col-sm-12
col-md-1
col-lg-1
col-xs-12
col-sm-12
col-md-7
col-lg-7
  • add-style
  • lp-body-content
Covid19 Vaccine
content/dam/photos/768x384/2022/aug/Covid-Vaccine-Generic-WEB.jpeg

The World Bank Group is taking broad, fast action to help developing countries strengthen their pandemic response, increase disease surveillance, improve public health interventions, and help the private sector continue to operate and sustain jobs. At the forefront of the multilateral crisis response, the WBG delivered an unprecedented $204 billion in financial support to public and private sector clients in the first two calendar years of the crisis (CY20-21), of which $135 billion is from IBRD/IDA, $60 billion from IFC and $9 billion from MIGA.

As of June 30, 2022, the World Bank approved operations to support vaccine rollout in 78 countries amounting to $10.1 billion. Through this, the World Bank Group is working with partners on the largest vaccination effort in history to stop the COVID-19 pandemic.

On April 2, 2020 the first group of projects using the dedicated COVID-19 Fast-Track Facility (also called the COVID-19 Strategic Preparedness and Response Program (SPRP)), amounting to $1.9 billion and assisting 25 countries, was rolled out.

On May 19, 2020 the Bank Group announced its emergency operations to fight COVID-19 have reached 100 developing countries – home to 70% of the world’s population. On October 13, 2020, $12 billion was approved for developing countries to finance the purchase and distribution of COVID-19 vaccines, tests, and treatments for their citizens.

On June 30, 2021 President Malpass announced the expansion of financing available for COVID-19 vaccine financing to $20 billion over the next 18 months, adding $8 billion to the previously announced $12 billion.

In addition, we are working worldwide to redeploy resources in existing World Bank financed projects, including through restructuring and use of projects’ emergency components as well as contingent financing instruments designed for catastrophes, including pandemics.

The lists below include:

  • Projects that are supported by the COVID-19 Fast-Track Facility, including support for COVID vaccine acquisition and/or deployment;
  • Projects with support from IBRD and IDA, with components responding to COVID-19, and projects that receive COVID-19 funding through restructuring, redeployment, and reallocation of existing resources.

These lists are updated as projects are processed and approved.

Projects that are supported by the COVID-19 Fast-Track Facility (including support for vaccines)

Africa

Benin, Additional financing for vaccines

Burkina Faso
Burundi, Additional financing
Cabo Verde, Additional financing for vaccines, Third additional financing for vaccines
Cameroon, Additional financing for vaccines
Central African Republic, Additional financing for vaccines
Chad, Additional financing for vaccines
Comoros Additional financing for vaccines
Côte d’Ivoire, Additional financing for vaccines
Democratic Republic of Congo, Additional financing for vaccines
Eswatini, Additional financing for vaccines
Ethiopia, Additional financing for vaccines, Second additional financing, Third additional financing
Gabon, Additional financing for vaccines
The Gambia, Second additional financing for vaccines, Third additional financing
Ghana, Additional financing, Additional financing for vaccines
Guinea, Additional financing for vaccines
Guinea Bissau, Additional financing
Kenya, Additional financing for vaccines

Lesotho, Additional financing for vaccines
Liberia, Additional financing for vaccines
Madagascar for vaccines, Additional financing
Malawi, Additional financing for vaccines
Mali, Additional financing for vaccines
Mauritania, Additional financing for vaccines, Second additional financing
Mozambique, Additional financing for vaccines

Niger, Additional financing for vaccines
Nigeria, Additional financing for vaccines
Republic of the Congo, Additional financing for vaccines
Rwanda, Additional financing, Second additional financing for vaccines
Sao Tome e Principe, Additional financing for vaccines
Senegal
Sierra Leone, Additional financing for vaccines, Second additional financing for vaccines
Somalia
South Africa
South Sudan Additional financing for vaccinesTogo, Additional financing for vaccines, Second additional financing
Uganda, Additional financing for vaccines
Zambia, Additional financing for vaccines
Zimbabwe

East Asia and Pacific
Cambodia, Additional financing, Additional financing for vaccines
Fiji
Indonesia, Additional financing for vaccines
Kiribati
Lao PDR, Additional financing for vaccines
Marshall Islands
Mongolia, Additional financing for vaccines
Myanmar, Additional financing
Papua New Guinea, Additional financing for vaccines
Philippines, Additional financing for vaccines, Second additional financing
Samoa
Solomon Islands
Timor-Leste
Europe and Central Asia
Albania
Belarus
Bosnia and Herzegovina
Georgia, Additional financing for vaccines
Kosovo, Additional financing for vaccines
Kyrgyz Republic
Moldova, Additional financing for vaccines
North Macedonia
Serbia
Tajikistan, Additional financing, Additional Financing and Restructuring, Additional financing for vaccines
Türkiye, Additional financing
Ukraine, Additional financing
Uzbekistan, Additional financing
Latin America and the Caribbean
Argentina, Additional financing for vaccines
Belize
Costa Rica
Ecuador, Additional financing for vaccines (Spanish)
El Salvador, Additional financing for vaccines (Spanish)
Guatemala
Guyana, Additional financing for vaccines
Haiti, Additional financing for vaccines
Honduras, Additional financing for vaccines (Spanish)
Nicaragua
Panama, Additional financing for vaccines
Paraguay
Peru
Trinidad and Tobago
Uruguay
Middle East and North Africa
Djibouti
Egypt
Iran
Iraq
Jordan, Additional financing for vaccines
Tunisia, Additional financing for vaccines
Yemen, Additional financing for vaccines
South Asia
Afghanistan, Additional financing for vaccines
Bangladesh, Additional financing for vaccines
Bhutan
India
Maldives
Nepal, Additional financing for vaccines
Pakistan
Sri Lanka, Additional financing, Second additional financing for vaccines, Third additional financing for vaccines

Projects with support from IBRD and IDA, with components responding to COVID-19 and projects with other forms of finance/redeploying of existing projects

Africa

Angola

Benin

Burkina Faso

Burundi

Cabo Verde

Cameroon

Central African Republic

Chad

Comoros

Congo, Republic of

Congo, Democratic Republic of

Eastern Africa

Eswatini

Ethiopia

The Gambia

Ghana

Guinea

Guinea-Bissau

Kenya

Liberia

  • Regional Disease Surveillance Systems Enhancement Project (REDISSE)
  • REDISSE Phase II

Madagascar

Malawi

Mali

Mauritania

Mozambique

Niger

Nigeria

Rwanda

São Tomé and Príncipe

Senegal

Seychelles

Sierra Leone

Somalia

South Sudan

Sudan

Tanzania

Togo

Uganda

Western Africa

Zambia

East Asia and Pacific

Cambodia

China

Federated States of Micronesia

Fiji

Indonesia

Kiribati

Lao PDR

Marshall Islands

Mongolia

Myanmar

Philippines

Samoa

Solomon Islands

Tonga

Tuvalu

Vanuatu

Vietnam

Europe and Central Asia

Albania

Bosnia and Herzegovina

Central Asia

Croatia

Georgia

Kyrgyz Republic

North Macedonia

Turkey

Ukraine

Uzbekistan

Latin America and the Caribbean

Argentina

Bahamas

Belize

Bolivia

Brazil

Colombia

Costa Rica

Dominica

Dominican Republic

Ecuador

Grenada

Guatemala

Guyana

Haiti

Honduras

Jamaica

Mexico

Nicaragua

Panama

Peru

Saint Lucia

Saint Vincent and the Grenadines

Suriname

Uruguay

Middle East and North Africa

Djibouti

Egypt, Arab Republic of

Iraq

Jordan

Lebanon

Morocco

Tunisia

West Bank and Gaza

Yemen

South Asia

Afghanistan

Bangladesh

Bhutan

India

Maldives

Nepal

Pakistan

Sri Lanka (press release for projects below)

col-xs-12
col-sm-12
col-md-1
col-lg-1
col-xs-12
col-sm-12
col-md-3
col-lg-3
lp-heading-top-large
lp-heading-bottom-large